• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Specialty Drug Tier Grows for Many Exchange Benefit Designs

Article

Certain exchange benefit plans have recently begun to place all specialty medications for complex diseases on the highest drug formulary cost-sharing tier, according to an analysis from Avalere Health.

Certain exchange benefit plans have recently begun to place all specialty medications for complex diseases on the highest drug formulary cost-sharing tier, according to an analysis from Avalere Health.

The report found that plans placed 5 of the 20 drug classes studied on the specialty tier and of the multiple sclerosis agents alone, 50% of plans placed both the branded drugs and generic versions on the highest tier. Additionally, a subset of plans in 10 drug classes listed all single-source branded drugs in a class on the specialty tier and 8 of those drug classes that consisted of single-source branded drugs were more likely to be listed on the highest cost-sharing tier in 2015 than in 2014.

“Enrolling in a plan that places all medications for a particular disease on the specialty tier can mean significant out-of-pocket costs for consumers, particularly if they do not qualify for cost sharing reductions,” Caroline Pearson, vice president of Avalere, said in a statement. “Plans that place some drugs in a class on lower tiers may allow consumers to find lower cost alternatives.”

Taking into account individual based variables, such as subsidies, out-of-pocket-limits and overall plan benefit design, researchers at Avalere Health highlighted that 8 in 10 individuals received a premium tax credit by selecting an exchange plan in 2015, which lowered monthly premium costs by nearly 75%.

Related Videos
Camilla Levister
dr daniel ontaneda
James Robinson, PhD, MPH, University of California, Berkeley
Shauna Downs, PhD, MS | Image Credit: Rutgers School of Public Health
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.